BrainsWay (Nasdaq:BWAY) announced plans for two new feasibility trials evaluating its neurostimulation technology.
The studies both involve BrainsWay’s patented rotational field TMS (or Deep TMS 360°). The company’s transcranial magnetic stimulation (TMS) method of stimulation enables the activation of more neurons in the brain.
With the new rotational field system under evaluation, two orthogonal TMS coils are placed perpendicular to one another. Operated with a time lag, they induce a circulatory rotating electric field. This results in uniform stimulation of neurons oriented along a wide variety of directions in the targeted brain region.
It all takes place within less than a millisecond.
BrainsWay wants to assess the potential clinical impact of this technology in two new studies. One tests the safety and efficacy in the field of rehabilitation following a stroke. The other looks at obsessive-compulsive disorder (OCD) with an accelerated protocol. BrainsWay already has FDA clearance for Deep TMS to use OCD using the standard daily protocol with its H7 coil. The new study assesses if rotational field stimulation could improve outcomes while reducing the length of the standard treatment.
“We are proud to continue to be at the forefront of innovation in the field of noninvasive brain stimulation,” said Hadar Levy, BrainsWay CEO. “We believe that our rotational field technology holds significant potential to change the current TMS paradigm.”